The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
The approval of Augmentin XR, granted to USAntibiotics, directly supports the CNPV program’s goals
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
The PCR-based test, delivered via Roche’s cobas liat system, allows results to be obtained during a patient consultation in GP practices and Emergency Rooms
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Surgical site infections and antimicrobial resistance remain major challenges globally
These initiatives will harness top scientific talent and advanced AI technologies to develop new ways to slow the rise of drug-resistant infections
The formulation is backed by over 80 clinical trials and 200 scientific publications
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Subscribe To Our Newsletter & Stay Updated
